Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

29

Revenue 2017

Soliris

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Soliris was produced by Alexion.

US, EU regulators start review of Roche’s Soliris rival satralizumab

US, EU regulators start review of Roche’s Soliris rival satralizumab

paralysis. At the moment the only approved treatment in the US is Alexion’s complement C5 inhibitor  Soliris (eculizumab), which got a green light from the FDA in June, and there ... Viela thinks inebilizumab has a dosing advantage over both Soliris

Alexion eyes Soliris combo with $930m deal to buy Achillion

Alexion eyes Soliris combo with $930m deal to buy Achillion paroxysmal nocturnal haemoglobinuria (PNH), a rare disease whose treatment is currently dominated by Alexion’s blockbuster complement C5 inhibitor  Soliris (eculizumab). ... combination with Soliris in PNH – and follow-up ACH-5228 in phase 1.

Roche presents new data in NMOSD, could challenge Alexion's Soliris

Roche presents new data in NMOSD, could challenge Alexion's Soliris Reduced risk of relapse by 55%. Roche has presented new data on satralizumab for neuromyelitis optica spectrum disorder (NMOSD),  setting it up for a potential market battle with Alexion’s Soliris. ... progression. Alexion’s Soliris received FDA

Medimmune-born Viela files $150m IPO, eyes first product launch

Medimmune-born Viela files $150m IPO, eyes first product launch NMOSD patients have few treatment options, although Alexion’s blockbuster complement C5 inhibitor  Soliris(eculizumab) recently became the first drug to be FDA-approved for this indication.

Amgen takes aim at Alexion’s patents for Soliris

Amgen takes aim at Alexion’s patents for Soliris Now, it’s filed a patent infringement action against Alexion’s top-selling drug Soliris. ... In trials, Ultomiris matched Soliris for efficacy – with a trend towards superiority – and offers improved dosing.

1 2 3 4 5 6 7 8 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics